scholarly journals Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

The Lancet ◽  
2017 ◽  
Vol 389 (10066) ◽  
pp. 255-265 ◽  
Author(s):  
Achim Rittmeyer ◽  
Fabrice Barlesi ◽  
Daniel Waterkamp ◽  
Keunchil Park ◽  
Fortunato Ciardiello ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Randomised Controlled Trial ◽  
Small Cell Lung Cancer ◽  
Controlled Trial ◽  
Small Cell ◽  
Small Cell Lung ◽  
Open Label ◽  
Phase 3 ◽  
Previously Treated ◽  
Randomised Controlled

scholarly journals Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial

The Lancet ◽  
2015 ◽  
Vol 385 (9962) ◽  
pp. 36-42 ◽  
Author(s):  
Ben J Slotman ◽  
Harm van Tinteren ◽  
John O Praag ◽  
Joost L Knegjens ◽  
Sherif Y El Sharouni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Randomised Controlled Trial ◽  
Small Cell Lung Cancer ◽  
Controlled Trial ◽  
Small Cell ◽  
Thoracic Radiotherapy ◽  
Small Cell Lung ◽  
Phase 3 ◽  
Extensive Stage ◽  
Randomised Controlled

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

The Lancet ◽  
2016 ◽  
Vol 387 (10030) ◽  
pp. 1837-1846 ◽  
Author(s):  
Louis Fehrenbacher ◽  
Alexander Spira ◽  
Marcus Ballinger ◽  
Marcin Kowanetz ◽  
Johan Vansteenkiste ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Randomised Controlled Trial ◽  
Controlled Trial ◽  
Small Cell ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Open Label ◽  
Open Label Phase ◽  
Previously Treated ◽  
Randomised Controlled
Sign in / Sign up

Export Citation Format

Share Document